# BioPharmSignal LiveFeed

A current stream of biotech company news, clinical updates, FDA events, financing headlines, partnerships, and commercial launch updates.

Canonical URL: https://biopharmsignal.com/livefeed

## Latest News

- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) — Source: MorphoSys
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640) — Source: GSK plc
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) — Source: Rani Therapeutics
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) — Source: Innate Pharma
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) — Source: ACADIA Pharmaceuticals Inc.
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9) — Source: Enlivex Therapeutics
- 2026-07-20 12:30 EST — VIRI — [Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026](https://biopharmsignal.com/news/VIRI/dogwood-enrolls-first-200-patients-in-ongoing-halneuron-phase-2b-chemotherapy-in-dd9f404d) — Source: Virios Therapeutics
- 2026-07-20 12:00 EST — MNPR — [Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team](https://biopharmsignal.com/news/MNPR/monopar-advances-launch-readiness-with-addition-of-veteran-commercial-executive--6af36ead) — Source: Monopar
- 2026-07-20 11:06 EST — USNA — [USANA Health Sciences Renews Four-Year Partnership with Nordiq Canada, Deepening Commitment to Clean Sport and Elite Athlete Nutrition](https://biopharmsignal.com/news/USNA/usana-health-sciences-renews-four-year-partnership-with-nordiq-canada-deepening--7aaacadb) — Source: Usana Health Sciences, Inc.
- 2026-07-20 11:05 EST — HLF — [Herbalife CFO to Participate in Maxim Group “Health, Wellness & Longevity” Virtual Conference on July 22](https://biopharmsignal.com/news/HLF/herbalife-cfo-to-participate-in-maxim-group-health-wellness-longevity-virtual-co-145c5335) — Source: Herbalife Nutrition
- 2026-07-20 10:59 EST — BMY — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 10:00 EST — GLSI — [Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-provides-clinical-updates-on-flamingo-01-99f074c4) — Source: Greenwich LifeSciences
- 2026-07-20 07:00 EST — GSK — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 20:30 EST — DMAC — [DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/DMAC/diamedica-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-58a5078e) — Source: DiaMedica Therapeutics
- 2026-07-17 13:00 EST — IDYA — [IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-esmo-2026-presentations-for-darovasertib-and-ide849-3e0620d8) — Source: IDEAYA Biosciences
- 2026-07-17 12:00 EST — AMRX — [Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations](https://biopharmsignal.com/news/AMRX/amneal-expands-iohexol-injection-portfolio-with-u-s-fda-approval-of-additional-s-5f3ad56b) — Source: Amneal Pharmaceuticals
- 2026-07-17 12:00 EST — MOR — [Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN](https://biopharmsignal.com/news/MOR/novartis-fabhalta-iptacopan-receives-fda-traditional-approval-as-first-and-only--ec34f769) — Source: MorphoSys
- 2026-07-17 09:00 EST — GSK — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 13:00 EST — INBX — [Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million](https://biopharmsignal.com/news/INBX/inhibrx-announces-amended-loan-agreement-with-oxford-finance-expanding-total-fac-d29cd85b) — Source: Inhibrx
- 2026-07-16 12:48 EST — ARTL — [Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions](https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-results-from-a-nonclinical-osteoarthritis-study-sup-fa16911f) — Source: Artelo Biosciences
- 2026-07-16 12:31 EST — MRK — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:30 EST — INGN — [Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/INGN/inogen-to-report-second-quarter-2026-financial-results-on-august-6-2026-29d58db2) — Source: Inogen
- 2026-07-16 12:00 EST — ALNY — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-16 11:30 EST — VRAX — [Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement](https://biopharmsignal.com/news/VRAX/virax-biolabs-ceo-james-foster-provides-shareholder-update-following-fiscal-2026-e1b97d68) — Source: Virax Biolabs
- 2026-07-16 11:30 EST — GLSI — [Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01](https://biopharmsignal.com/news/GLSI/greenwich-lifesciences-announces-european-approval-for-combining-both-hla-popula-adf83f60) — Source: Greenwich LifeSciences
- 2026-07-16 11:05 EST — RLMD — [Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-report-second-quarter-2026-financial-results-on-thursday-a5332b5c) — Source: Relmada
- 2026-07-16 11:00 EST — INSM — [Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension](https://biopharmsignal.com/news/INSM/insmed-announces-positive-12-month-data-from-the-ongoing-open-label-extension-st-7880862e) — Source: Insmed
- 2026-07-15 20:30 EST — CCEL — [Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/CCEL/cord-blood-banking-leader-cryo-cell-reports-fiscal-second-quarter-2026-financial-7072363c) — Source: Cryo-Cell
- 2026-07-15 20:15 EST — PRI — [Primerica Schedules Second Quarter 2026 Financial Results Webcast](https://biopharmsignal.com/news/PRI/primerica-schedules-second-quarter-2026-financial-results-webcast-8557ad05) — Source: PRIMERICA
- 2026-07-15 20:05 EST — ACAD — [Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-to-announce-second-quarter-2026-financial-results-on-augu-562a4f56) — Source: ACADIA Pharmaceuticals Inc.
- 2026-07-15 13:40 EST — GSK — [GSK completes acquisition of Nuvalent, Inc.](https://biopharmsignal.com/news/GSK/gsk-completes-acquisition-of-nuvalent-inc-c44954f4) — Source: GSK plc
- 2026-07-15 13:05 EST — TNXP — [Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models](https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-publication-in-the-peer-reviewed-journal-of-viro-14c8c277) — Source: Tonix Pharmaceuticals
- 2026-07-15 12:31 EST — MRK — [KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy](https://biopharmsignal.com/news/MRK/keytruda-pembrolizumab-as-monotherapy-significantly-improved-progression-free-su-ceac984b) — Source: Merck
- 2026-07-15 12:31 EST — MRK — [Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026](https://biopharmsignal.com/news/MRK/merck-to-present-new-data-on-daily-weekly-and-monthly-options-across-its-hiv-tre-f70a5c44) — Source: Merck
- 2026-07-15 12:30 EST — LIXT — [NOMAD Power Solutions Strengthens Subsidiary Executive Leadership](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-strengthens-subsidiary-executive-leadership-694eafe1) — Source: Lixte Biotechnology Holdings
- 2026-07-15 12:00 EST — RANI — [Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing](https://biopharmsignal.com/news/RANI/rani-therapeutics-announces-positive-initial-phase-1a-data-for-rt-114-for-the-tr-e7d21ddc) — Source: Rani Therapeutics
- 2026-07-15 12:00 EST — EVGN — [AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities](https://biopharmsignal.com/news/EVGN/agplenus-launches-novel-ai-model-for-predicting-antifungal-potency-expanding-che-3e490172) — Source: Evogene
- 2026-07-15 12:00 EST — AMRN — [Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026](https://biopharmsignal.com/news/AMRN/amarin-to-report-second-quarter-2026-financial-results-and-host-conference-call--ba7d316a) — Source: Amarin Corporation
- 2026-07-15 12:00 EST — ALNY — [Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurologi](https://biopharmsignal.com/news/ALNY/alnylam-highlights-progress-with-neuroscience-programs-at-aaic-2026-showcasing-p-508fc61d) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-15 11:45 EST — INTS — [Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)](https://biopharmsignal.com/news/INTS/intensity-therapeutics-inc-restarts-patient-treatment-in-the-randomized-presurgi-51761e30) — Source: Intensity Therapeutics
- 2026-07-15 11:30 EST — CLRB — [Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-announces-publication-of-phase-1-study-of-iopofosine-i-131-1d5d4326) — Source: Cellectar Biosciences
- 2026-07-15 11:00 EST — AXGN — [Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026](https://biopharmsignal.com/news/AXGN/axogen-inc-to-report-second-quarter-2026-financial-results-on-july-29-2026-56aa71ab) — Source: AxoGen
- 2026-07-15 11:00 EST — BRKR — [Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood](https://biopharmsignal.com/news/BRKR/bruker-expands-infection-detection-portfolio-with-acquisition-of-metagenomic-mng-36c3ebd1) — Source: Bruker
- 2026-07-14 20:15 EST — USNA — [USANA Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/USNA/usana-schedules-second-quarter-2026-earnings-release-and-conference-call-d0dc753b) — Source: Usana Health Sciences, Inc.
- 2026-07-14 20:03 EST — VANI — [Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026](https://biopharmsignal.com/news/VANI/vivani-medical-to-present-at-the-emerging-growth-conference-on-july-15-2026-793033b6) — Source: Vivani Medical
- 2026-07-14 13:00 EST — XOMA — [XOMA Royalty Announces Closing of Its Acquisition by Ligand](https://biopharmsignal.com/news/XOMA/xoma-royalty-announces-closing-of-its-acquisition-by-ligand-6ca7a63d) — Source: XOMA Corporation
- 2026-07-14 12:47 EST — ARTL — [Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026](https://biopharmsignal.com/news/ARTL/artelo-biosciences-issues-reminder-to-shareholders-to-vote-in-advance-of-annual--371c2cf4) — Source: Artelo Biosciences
- 2026-07-14 12:32 EST — ICCM — [IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation](https://biopharmsignal.com/news/ICCM/icecure-expands-u-s-commercial-team-to-meet-surging-demand-for-prosense-cryoabla-7980c317) — Source: IceCure Medical
- 2026-07-14 12:13 EST — ZBH — [Zimmer Biomet Names Chintan Desai President of Asia Pacific Region](https://biopharmsignal.com/news/ZBH/zimmer-biomet-names-chintan-desai-president-of-asia-pacific-region-4a803d7f) — Source: Zimmer Biomet
- 2026-07-14 12:00 EST — ENSC — [Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant](https://biopharmsignal.com/news/ENSC/ensysce-biosciences-awarded-5-3-million-installment-in-nida-funding-completing-m-ee1ecc0e) — Source: Ensysce Biosciences
- 2026-07-14 12:00 EST — IKT — [Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility](https://biopharmsignal.com/news/IKT/inhibikase-therapeutics-announces-sale-of-50-million-of-shares-through-its-at-th-30edf4cb) — Source: Inhibikase Therapeutics
- 2026-07-14 12:00 EST — PMN — [ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026](https://biopharmsignal.com/news/PMN/promis-neurosciences-reports-first-human-evidence-of-amyloid-beta-oligomer-targe-5218a89a) — Source: ProMIS Neurosciences
- 2026-07-14 11:30 EST — IRWD — [Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients](https://biopharmsignal.com/news/IRWD/ironwood-appoints-dr-jeffrey-silber-chief-medical-officer-and-head-of-research-a-b6d13a27) — Source: Ironwood Pharmaceuticals
- 2026-07-14 11:02 EST — SPRO — [Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-105-million-non-recourse-non-dilutive-financing-bac-d8d87fa7) — Source: Spero Therapeutics
- 2026-07-14 11:00 EST — BEAT — [HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device](https://biopharmsignal.com/news/BEAT/heartbeam-awarded-new-u-s-patent-expanding-acoustic-sensing-and-fluid-monitoring-e0c78764) — Source: HeartBeam
- 2026-07-14 08:00 EST — ACXP — [Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection](https://biopharmsignal.com/news/ACXP/acurx-pharmaceuticals-announces-scientific-poster-presentation-of-ibezapolstat-s-7d80a5a2) — Source: Acurx Pharmaceuticals
- 2026-07-13 18:59 EST — HLF — [Herbalife Named to TIME's List of America’s Best Companies 2026](https://biopharmsignal.com/news/HLF/herbalife-named-to-time-s-list-of-america-s-best-companies-2026-14afe60c) — Source: Herbalife Nutrition
- 2026-07-13 13:02 EST — ARTL — [Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy](https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-positive-results-with-art27-13-in-a-nonclinical-mod-86480dfe) — Source: Artelo Biosciences
- 2026-07-13 13:00 EST — ENLV — [Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis](https://biopharmsignal.com/news/ENLV/enlivex-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-8b6ad971) — Source: Enlivex Therapeutics
- 2026-07-13 12:42 EST — EWTX — [Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline](https://biopharmsignal.com/news/EWTX/edgewise-therapeutics-completes-sale-of-sevasemten-for-up-to-2-65-billion-streng-cafc855d) — Source: Edgewise Therapeutics
- 2026-07-13 12:14 EST — ZBH — [Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ZBH/zimmer-biomet-announces-webcast-and-conference-call-of-second-quarter-2026-finan-eeeb31b3) — Source: Zimmer Biomet
- 2026-07-13 12:01 EST — AEMD — [Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®](https://biopharmsignal.com/news/AEMD/aethlon-medical-continues-to-observe-directional-changes-in-second-cohort-of-aus-9cc3f8f7) — Source: Aethlon Medical
- 2026-07-13 12:00 EST — GLPG — [Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi](https://biopharmsignal.com/news/GLPG/lakefront-announces-paulo-fontoura-has-resigned-from-its-board-following-his-app-f92a2665) — Source: Galapagos NV
- 2026-07-13 12:00 EST — BAVN — [News | Bavarian Nordic](https://biopharmsignal.com/news/BAVN/news-bavarian-nordic-b9e90c06) — Source: Bavarian Nordic
- 2026-07-13 12:00 EST — TCMD — [Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients](https://biopharmsignal.com/news/TCMD/tactile-medical-enters-exclusive-u-s-distribution-agreement-with-elastimed-for-i-116aea64) — Source: Tactile Systems Technology, Inc.
- 2026-07-13 11:00 EST — TNXP — [Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®](https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-major-managed-medicare-payer-agreement-for-tonmy-bb25eccc) — Source: Tonix Pharmaceuticals
- 2026-07-13 10:59 EST — BMY — [U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma](https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-drug-applica-b21b9788) — Source: BMYBristol-Myers Squibb Company
- 2026-07-13 07:00 EST — GSK — [Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer](https://biopharmsignal.com/news/GSK/jemperli-dostarlimab-achieves-sustained-clinical-complete-responses-in-dmmr-msi--18610cf7) — Source: GSK plc
- 2026-07-10 20:05 EST — VRAX — [Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds](https://biopharmsignal.com/news/VRAX/virax-biolabs-group-limited-announces-closing-of-exercise-of-preferred-investmen-cc034f76) — Source: Virax Biolabs
- 2026-07-10 19:01 EST — MRK — [FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)](https://biopharmsignal.com/news/MRK/fda-approves-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyal-7cdef535) — Source: Merck
- 2026-07-10 13:24 EST — DGX — [One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns](https://biopharmsignal.com/news/DGX/one-in-five-american-workers-tested-had-a-positive-hair-drug-test-in-2025-signal-cb4ae34e) — Source: Quest Diagnostics
- 2026-07-10 12:04 EST — SEM — [Select Medical Holdings Corporation to be Acquired by Consortium Led by Robert A. Ortenzio, Martin F. Jackson and WCAS | Select Medical](https://biopharmsignal.com/news/SEM/select-medical-holdings-corporation-to-be-acquired-by-consortium-led-by-robert-a-1855a81b) — Source: Select Medical
- 2026-07-10 12:00 EST — VERA — [Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/VERA/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-0ef52228) — Source: Vera Therapeutics
- 2026-07-10 11:00 EST — GSK — [GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population](https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-b379a2b1) — Source: GSK plc
- 2026-07-10 10:06 EST — MRK — [FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC) - Merck.com](https://biopharmsignal.com/news/MRK/fda-approves-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyal-bc1625e5) — Source: Merck
- 2026-07-10 10:06 EST — MRK — [Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV - Merck.com](https://biopharmsignal.com/news/MRK/merck-announces-new-agreement-with-adap-crisis-task-force-to-improve-access-and--4390af46) — Source: Merck
- 2026-07-10 10:06 EST — MRK — [Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - Merck.com](https://biopharmsignal.com/news/MRK/merck-to-hold-second-quarter-2026-sales-and-earnings-conference-call-aug-4-merck-44a90bf3) — Source: Merck
- 2026-07-10 03:30 EST — BBLG — [Bone Biologics Announces Closing of $5.0 Million Public Offering - Bone Biologics](https://biopharmsignal.com/news/BBLG/bone-biologics-announces-closing-of-5-0-million-public-offering-bone-biologics-b7499bd9) — Source: Bone Biologics
- 2026-07-09 21:44 EST — ELGXQ — [3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease - Endologix](https://biopharmsignal.com/news/ELGXQ/3-year-detour2-results-demonstrate-sustained-symptom-relief-and-limb-preservatio-7b9855b1) — Source: Endologix
- 2026-07-09 20:15 EST — BDX — [BD to Announce Financial Results for its Third Quarter of Fiscal 2026](https://biopharmsignal.com/news/BDX/bd-to-announce-financial-results-for-its-third-quarter-of-fiscal-2026-fae7aaa2) — Source: Becton Dickinson
- 2026-07-09 20:05 EST — RANI — [Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates](https://biopharmsignal.com/news/RANI/rani-therapeutics-announces-research-and-development-collaboration-with-pegbio-t-5a7630da) — Source: Rani Therapeutics
- 2026-07-09 20:05 EST — SERA — [PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE](https://biopharmsignal.com/news/SERA/prime-subgroup-analysis-demonstrates-22-reduction-in-nicu-admissions-in-first-ti-1eec527c) — Source: Sera Prognostics
- 2026-07-09 20:05 EST — AMRX — [Amneal to Report Second Quarter 2026 Results on July 30, 2026](https://biopharmsignal.com/news/AMRX/amneal-to-report-second-quarter-2026-results-on-july-30-2026-e7677e7f) — Source: Amneal Pharmaceuticals
- 2026-07-09 19:07 EST — MRK — [Gilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment - Merck.com](https://biopharmsignal.com/news/MRK/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-eval-bb1d1ada) — Source: Merck
- 2026-07-09 18:25 EST — ALNY — [Alnylam to Webcast Presentations at Upcoming Investor Conferences](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-presentations-at-upcoming-investor-conferences-50fb6676) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:25 EST — ALNY — [New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutris](https://biopharmsignal.com/news/ALNY/new-data-analyses-presented-at-heart-failure-2026-demonstrate-robust-and-consist-d10768e9) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — ALNY — [Alnylam Issues 2025 Corporate Responsibility Report](https://biopharmsignal.com/news/ALNY/alnylam-issues-2025-corporate-responsibility-report-62023cfe) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — ALNY — [Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics](https://biopharmsignal.com/news/ALNY/alnylam-and-inceptive-form-strategic-ai-collaboration-to-accelerate-the-discover-3d8b2b06) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — ALNY — [Alnylam to Host Tenth “RNAi Roundtable” Webcast Series](https://biopharmsignal.com/news/ALNY/alnylam-to-host-tenth-rnai-roundtable-webcast-series-3988e623) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 17:35 EST — VRAX — [Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds](https://biopharmsignal.com/news/VRAX/virax-biolabs-group-limited-announces-exercise-of-preferred-investment-options-f-60095931) — Source: Virax Biolabs
- 2026-07-09 15:57 EST — HEPA — [Hepion Pharmaceuticals Successfully Completes Application to the OTCQB – Hepion Pharmaceuticals](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-successfully-completes-application-to-the-otcqb-hepion-ph-ebadb4d3) — Source: Hepion Pharmaceuticals
- 2026-07-09 15:46 EST — EGTX — [Exercise of options under employee stock option program and notification of insider trading - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/exercise-of-options-under-employee-stock-option-program-and-notification-of-insi-e6812443) — Source: Egetis
- 2026-07-09 15:43 EST — CRNX — [Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities | Crinetics](https://biopharmsignal.com/news/CRNX/crinetics-and-leading-patient-groups-launch-everyday-advocacy-initiative-to-empo-2503d5d7) — Source: Crinetics Pharmaceuticals
- 2026-07-09 15:43 EST — CRNX — [Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 | Crinetics](https://biopharmsignal.com/news/CRNX/crinetics-presents-full-results-from-phase-2-trial-of-atumelnant-in-congenital-a-cc021e52) — Source: Crinetics Pharmaceuticals
- 2026-07-09 15:23 EST — ADXN — [Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026](https://biopharmsignal.com/news/ADXN/addex-therapeutics-to-report-2026-first-quarter-financial-results-and-host-confe-bf43b1f6) — Source: Addex Therapeutics
- 2026-07-09 15:23 EST — ADXN — [Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ADXN/addex-therapeutics-reports-first-quarter-2026-financial-results-and-provides-cor-3735e823) — Source: Addex Therapeutics
- 2026-07-09 15:23 EST — ADXN — [Addex Shareholders Approve All Resolutions at Annual General Meeting](https://biopharmsignal.com/news/ADXN/addex-shareholders-approve-all-resolutions-at-annual-general-meeting-d034b014) — Source: Addex Therapeutics
- 2026-07-09 15:22 EST — ACON — [Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal](https://biopharmsignal.com/news/ACON/aclarion-rejects-echo-lake-capital-s-unsolicited-acquisition-proposal-1610a9fa) — Source: Aclarion
- 2026-07-09 15:22 EST — ACON — [Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform](https://biopharmsignal.com/news/ACON/aclarion-partners-with-pria-healthcare-to-advance-reimbursement-and-commercial-a-d8824477) — Source: Aclarion
- 2026-07-09 15:22 EST — ACON — [Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub](https://biopharmsignal.com/news/ACON/aclarion-to-present-at-the-planet-microcap-las-vegas-powered-by-microcapclub-07382a59) — Source: Aclarion